Moreover, through the repurposing of a clinically used small-molecule inhibitor verteporfin, it is possible to alter TGFβ/SMAD signaling in vivo to investigate the role of TGFβ/Hippo pathway integration in heart development and heart disease. The gene discussed is TGFB1; the disease is heart disorder.